Clinical Trial Update: Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial overview of ferric carboxymaltose in patients with type 2 diabetes mellitus and iron deficiency; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: GWT-TUD GmbH | Conditions: Type 2 Diabetes Mellitus, Iron Deficiency | Phase 3 | Status: COMPLETED